A Proposal to expand the IMMPACT Initiative to other …

A primary impetus for the development of the FDA draft guidance was a concern for physician and patient understanding of the information presented in the labeling of drugs. The overarching issue is determining how we can best communicate results of trials to facilitate clinical decision making among patients, providers, and policy makers ... ................
................